Terminated PHASE3 INTERVENTIONAL NCT00047632

Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer

Interferon Gamma-1b in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First Line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma.

Sponsor: InterMune

Conditions Ovarian Carcinoma Peritoneal Carcinoma

Interventions Interferon gamma-1b

Updated 5 times since 2017 Last updated: Oct 30, 2007 Started: Oct 31, 2001 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

futility

Other terminated trials from InterMune

See all terminations from InterMune

A PHASE3 clinical study on Ovarian Carcinoma and Peritoneal Carcinoma, this trial is terminated or withdrawn. The trial is conducted by InterMune and has accumulated 5 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

InterMune

Data source: InterMune

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brisbane, United States